Previous
Previous

Fauna Bio CTO Linda Goodman presented at MLxBio on our enhanced ML approach to target and therapeutics discovery using our proprietary disease resistance datasets and integration with human genomics.

Next
Next

Fauna Bio CEO, Ashley Zehnder speaks to founders on making the transition from academia to industry in the longevity field.